Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

mRNA CAR T Cell Therapy Receives FDA’s Rare Pediatric Designation to Treat Juvenile Dermatomyositis

Michele B. Kaufman, PharmD, BCGP  |  January 30, 2025

FDA has granted Descartes-08, an mRNA chimeric antigen receptor T cell therapy, a rare pediatric disease designation for the treatment of juvenile dermatomyositis.

Reproductive Health, Biosimilars & More in Focus at SOTA 2025

Ruth Jessen Hickman, MD  |  January 30, 2025

Reproductive health, biosimilars, IgG4-related disease and much more—five speakers give us a sneak peek into important topics being addressed at the ACR’s 2025 State-of-the-Art Clinical Symposium, April 4–6.

Answering the Call: Anisha Dua, MD, MPH, Looks Ahead to New Role on Committee on Training

Carina Stanton  |  January 29, 2025

Building on her experiences in her practice and through the ACR, this rheumatology leader and educator is eager to advance the work of the COT.

Skin disorder, pepper appearance from scleroderma, autoimmune disease male hand Skin disorder pepper appearance from vitiligo,scleroderma raynaud, medical concept autoimmune disease. Credit: Adobe Stock | Trsakaoe

Through Thick & Thin: Updates in Scleroderma

Jason Liebowitz, MD, FACR  |  January 22, 2025

Pulmonary hypertension and Raynaud’s phenomenon are just some of the symptoms patients with systemic sclerosis (SSc) may experience. Here are insights into the diagnosis and management of SSc.

Can MRI Predict Osteoarthritis’ Progression?

Arthritis & Rheumatology  |  January 22, 2025

In individuals without radiographic knee osteoarthritis (OA), Chang et al. investigated whether magnetic resonance imaging (MRI) defined knee OA at baseline was associated with incident radiographic and symptomatic disease during up to 11 years of follow-up. The researchers found the two current MRI definitions of knee OA may not adequately predict the development of radiographic and symptomatic disease.

Small Postcard, Big Impact: ACR’s New Grassroots Group Empowers Members to Be Rheumatology Advocates

From the College  |  January 20, 2025

Helping ACR/ARP members talk to lawmakers about rheumatology-related policy is a key part of the ACR’s advocacy efforts. A postcard-writing campaign to Congress highlights outreach efforts of a new member engagement working group.

Rheumatology 2025 State Legislative Preview

Joseph Cantrell, JD  |  January 20, 2025

As state legislatures begin to convene their sessions in 2025, several key issues related to rheumatology are expected to take center stage, including drug costs, utilization management, telehealth and copay accumulators.

2024 Federal Legislative Recap

From the College  |  January 20, 2025

Although many rheumatology priorities were cut from big funding bills in the 118th Congress, some policy victories and signals of progress set the stage for the new year

Answering the Call: Anisha Dua, MD, MPH, Looks Ahead to New Role as Committee on Training Chair

Carina Stanton  |  January 16, 2025

Building on her experiences in her practice and through the ACR, this rheumatology leader and educator is eager to advance the work of the COT.

Precision Medicine on a Population Level: Can Digital Health Technology Improve Access to Rheumatologic Care?

Daniel H. Solomon, MD, MPH, & Andrew Concoff, MD, FACR  |  January 16, 2025

Over our 25 years as rheumatologists, care has advanced greatly. We each completed our rheumatology training in the late 1990s when both infliximab and etanercept first arrived on the U.S. market, ushering in the era of biologics in rheumatology. Since this time, our greater understanding of the immunologic basis of many rheumatic diseases has translated…

  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 815
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences